EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG) and MorphoSys AG (NASDAQ:MOR) are two firms in the Biotechnology that compete against each other. Below is a comparison of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EyeGate Pharmaceuticals Inc.	1.65M	8.58	10.81M	-0.45	0.00
MorphoSys AG	N/A	0.00	N/A	-0.26	0.00

Demonstrates EyeGate Pharmaceuticals Inc. and MorphoSys AG earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 provides us EyeGate Pharmaceuticals Inc. and MorphoSys AG’s return on assets, net margins and return on equity.

	Net Margins	Return on Equity	Return on Assets
EyeGate Pharmaceuticals Inc.	-655.15%	-158.8%	-72.7%
MorphoSys AG	0.00%	0%	0%

Insider & Institutional Ownership

The shares of both EyeGate Pharmaceuticals Inc. and MorphoSys AG are owned by institutional investors at 49.8% and 7.3% respectively. Insiders held roughly 14.69% of EyeGate Pharmaceuticals Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
EyeGate Pharmaceuticals Inc.	0.23%	-9.52%	-17.29%	-22.3%	-25.59%	-5.61%
MorphoSys AG	2.87%	1.69%	-7.41%	-10.3%	0%	4.66%

For the past year EyeGate Pharmaceuticals Inc. had bearish trend while MorphoSys AG had bullish trend.

Summary

MorphoSys AG beats EyeGate Pharmaceuticals Inc. on 6 of the 9 factors.

EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing drug compositions and drug delivery systems for treating diseases and disorders of the eye. The company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients; and uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea. It is also developing the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial defects, as well as to accelerate re-epithelization of the ocular surface following surgery, injection, and other traumatic and non-traumatic conditions. In addition, the company is developing Eyegate II drug delivery system. It has license agreements with the University of Miami and its School of Medicine; subsidiaries of Valeant Pharmaceuticals International, Inc.; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. is headquartered in Waltham, Massachusetts.

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. Its product pipeline includes MOR208, a humanized monoclonal antibody that targets the antigen CD19, which is in Phase III clinical trial for the treatment of B cell malignancies; and MOR202, a human monoclonal HuCAL antibody directed against CD38, which is in Phase II trial for the treatment of multiple myeloma and other cancers. The company's product pipeline also comprises MOR103/GSK3196165, a human HuCAL antibody directed against granulocyte-macrophage colony-stimulating factor that is in Phase II clinical trial for treating rheumatoid arthritis and inflammatory hand osteoarthritis. In addition, its product pipeline includes MOR106, a human monoclonal antibody directed against IL-17C, which is in Phase I clinical trial for the treatment of atopic dermatitis; and MOR107 that is in preclinical investigation with a focus on oncology indications. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macao. The company was founded in 1992 and is headquartered in Planegg, Germany.